194413-58-6
Chemical Structure
(Z)-Semaxanib
Synonym(s): (Z)-SU5416
- CAS No.: 194413-58-6
- Formula:C15H14N2O
- Molecular Weight:238.29
IUPAC Name: (Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one
InChIKey: WUWDLXZGHZSWQZ-WQLSENKSSA-N
SMILES: O=C(NC1=C/2C=CC=C1)C2=C/C3=C(C)C=C(C)N3
Biological Activity: (Z)-Semaxanib ((Z)-SU5416) is a VEGF receptor tyrosine kinase inhibitor that blocks VEGF signaling through Flk-1/KDR. (Z)-Semaxanib inhibits angiogenesis by preventing new blood vessel formation. (Z)-Semaxanib induces cytotoxicity in liver cancer cells. (Z)-Semaxanib can be used in research on metastatic renal cell carcinoma, gastrointestinal stromal tumors, well-differentiated pancreatic neuroendocrine tumors, and solid tumors[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(Z)-Semaxanib | 99.72% | (Z)-Semaxanib ((Z)-SU5416) is a VEGF receptor tyrosine kinase inhibitor that blocks VEGF signaling through Flk-1/KDR. (Z)-Semaxanib inhibits angiogenesis by preventing new blood vessel formation. (Z)-Semaxanib induces cytotoxicity in liver cancer cells. (Z)-Semaxanib can be used in research on metastatic renal cell carcinoma, gastrointestinal stromal tumors, well-differentiated pancreatic neuroendocrine tumors, and solid tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ngai MH, et al. Photoinduced Isomerization and Hepatoxicities of Semaxanib, Sunitinib and Related 3-Substituted Indolin-2-ones. ChemMedChem. 2016 Jan 05;11(1):72-80. [Content Brief]
- [2]. Posocco B, et al. Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine. Journal of pharmaceutical and biomedical analysis. 2018 Oct 25;160:360-367.
- [3]. Zhao Y, et al. Simultaneous determination of Z-SU5416 and its interconvertible geometric E-isomer in rat plasma by LC/MS/MS. Journal of pharmaceutical and biomedical analysis. 2004 May 28;35(3):513-22. [Content Brief]
